Xenon Pharmaceuticals Inc.

VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025.

Conference Call/Webcast Information:   Date: Monday, May 12, 2025  Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast: Pre-register here  Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference ID: 5532604

A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts: 
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
[email protected]

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
[email protected]

View Comments